keytruda1

NICE knocks back MSD’s Keytruda for lung cancer indication

pharmafile | February 28, 2017 | News story | Research and Development, Sales and Marketing |  MSD, NICE, NSCLC, keytruda 

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for the treatment of untreated PD-L1-positive metastatic lung cancer.

NICE’s decision was spurred by the “immaturity of the data” provided by MSD, which made it impossible to accurately determine Keytruda’s overall survival benefits compared to current standard of care.

The institute ultimately determined that this lack of concrete supporting evidence meant that the cost-effectiveness estimate for the drug, which costs £2,630 for a 100mg vial, did not fall within its acceptable range, and as such will not be made available on the NHS.

Advertisement

The news comes as an unexpected misstep for the company after its immunotherapy drug scored a string of approval successes over the past few months, including in the indication of first-line treatment for metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have high PD-L1 expression in the EU.  

The decision is open for public consultation until 21 March.

Matt Fellows

Related Content

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma

NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for …

NICE recommends allergy immunotherapy tablets for younger children

NICE has recommended two sublingual immunotherapy tablets for children with moderate to severe allergic rhinitis …

NICE backs atogepant for acute migraine treatment

NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the …

The Gateway to Local Adoption Series

Latest content